Yared Belete Belay1, Eskinder Eshetu Ali2, Beate Sander3,4,5,6, Gebremedhin Beedemariam Gebretekle2,3,4. 1. School of Pharmacy, College of Health Sciences, Mekelle University, Mek'ele, Ethiopia. yared.belete@mu.edu.et. 2. Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. 3. Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, ON, Canada. 4. Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada. 5. Public Health Ontario, Toronto, ON, Canada. 6. ICES, Toronto, ON, Canada.
Abstract
BACKGROUND: Patients' health-related quality of life (HRQoL) and health state utility values are critical inputs in the clinical and economic evaluation of treatments for human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). However, information on health state utility values is lacking in the context of Ethiopia. Here, we aimed to assess HRQoL and determine health state utility values and factors that influence the values among HIV/AIDS patients in Ethiopia. METHODS: A cross-sectional study was conducted among 511 HIV/AIDS patients at Tikur Anbessa Specialized Hospital in Ethiopia. Patients aged 18 years or older were eligible for the interview and those who were mentally unstable and with hearing impairment were excluded from the study. We performed face-to-face interviews using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) in combination with EuroQol-Visual Analog Scales (EQ-VAS). Level-specific disutility coefficients obtained from the general population were used for computing utility values. Patients' health profiles were described using percentages and different statistical analysis were conducted to determine factors associated with the EQ-5D index and EQ-VAS scores. RESULTS: A total of 511 patients participated in the study. A higher proportion of patients reported slight or more severe problems on the anxiety/depression (55.2%) and pain/discomfort (51.3%) dimensions. The overall median utility value of HIV/AIDS patients was 0.94 (IQR = 0.87, 1) from the EQ-5D index and 80% (IQR = 70%, 90%) from the EQ-VAS scores. Demographic characteristics including age, occupational status, and household monthly income significantly affected patient's utility values. Moreover, statistically significant (p < 0.001) differences were seen between the EQ-5D index values of patients with different CD4 count intervals. Furthermore, number of medicines that the patients were taking at the time of the study and comorbidities were significantly associated with the EQ-5D utility index and EQ-VAS score, p < 0.001. CONCLUSIONS: The anxiety/depression and pain/ discomfort dimensions were identified to have critical influence in reducing the HRQoL of adult HIV/AIDS patients in the context of Ethiopia. The study is also the first to use the EQ-5D-5L tool to identify health state utility values for Ethiopian adult HIV/AIDS patients. Future economic evaluations of HIV/AIDS interventions are encouraged to employ the identified utility values.
BACKGROUND:Patients' health-related quality of life (HRQoL) and health state utility values are critical inputs in the clinical and economic evaluation of treatments for humanimmunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). However, information on health state utility values is lacking in the context of Ethiopia. Here, we aimed to assess HRQoL and determine health state utility values and factors that influence the values among HIV/AIDSpatients in Ethiopia. METHODS: A cross-sectional study was conducted among 511 HIV/AIDSpatients at Tikur Anbessa Specialized Hospital in Ethiopia. Patients aged 18 years or older were eligible for the interview and those who were mentally unstable and with hearing impairment were excluded from the study. We performed face-to-face interviews using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) in combination with EuroQol-Visual Analog Scales (EQ-VAS). Level-specific disutility coefficients obtained from the general population were used for computing utility values. Patients' health profiles were described using percentages and different statistical analysis were conducted to determine factors associated with the EQ-5D index and EQ-VAS scores. RESULTS: A total of 511 patients participated in the study. A higher proportion of patients reported slight or more severe problems on the anxiety/depression (55.2%) and pain/discomfort (51.3%) dimensions. The overall median utility value of HIV/AIDSpatients was 0.94 (IQR = 0.87, 1) from the EQ-5D index and 80% (IQR = 70%, 90%) from the EQ-VAS scores. Demographic characteristics including age, occupational status, and household monthly income significantly affected patient's utility values. Moreover, statistically significant (p < 0.001) differences were seen between the EQ-5D index values of patients with different CD4 count intervals. Furthermore, number of medicines that the patients were taking at the time of the study and comorbidities were significantly associated with the EQ-5D utility index and EQ-VAS score, p < 0.001. CONCLUSIONS: The anxiety/depression and pain/ discomfort dimensions were identified to have critical influence in reducing the HRQoL of adult HIV/AIDSpatients in the context of Ethiopia. The study is also the first to use the EQ-5D-5L tool to identify health state utility values for Ethiopian adult HIV/AIDSpatients. Future economic evaluations of HIV/AIDS interventions are encouraged to employ the identified utility values.
Entities:
Keywords:
EQ-5D-5L; EuroQol; HIV/AIDS; Quality of life; Utility
Authors: Mussa Keaei; Julien Kuhlmann; Rafael Conde; Silvia M A A Evers; Javier Gonzalez; Mark Govers; Mickael Hiligsmann Journal: Value Health Reg Issues Date: 2016-10-21
Authors: Camila Foresti Lemos; Marcelo Palmeira Rodrigues; Joel Russomano Paulo Veiga Journal: Health Qual Life Outcomes Date: 2015-12-21 Impact factor: 3.186
Authors: Mweete D Nglazi; Sacha J West; Joel A Dave; Naomi S Levitt; Estelle V Lambert Journal: BMC Public Health Date: 2014-07-03 Impact factor: 3.295
Authors: Maurice Michel; Alisha Wahl; Malena Anders; Saleh A Alqahtani; Wolfgang M Kremer; Peter R Galle; Christian Labenz; Daniel Grimm; Martin Sprinzl; Jörn M Schattenberg Journal: Qual Life Res Date: 2022-08-22 Impact factor: 3.440
Authors: Maurice Michel; Christian Labenz; Malena Anders; Alisha Wahl; Lisann Girolstein; Leonard Kaps; Wolfgang M Kremer; Yvonne Huber; Peter R Galle; Martin Sprinzl; Jörn M Schattenberg Journal: Hepatol Commun Date: 2022-04-12